Provided by Tiger Trade Technology Pte. Ltd.

Allarity Therapeutics Inc

1.07
0.0000
Post-market: 1.06-0.0100-0.93%18:26 EDT
Volume:150.25K
Turnover:160.64K
Market Cap:17.21M
PE:-0.80
High:1.10
Open:1.07
Low:1.04
Close:1.07
52wk High:2.35
52wk Low:0.6138
Shares:16.08M
Float Shares:16.06M
Volume Ratio:1.40
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3348
EPS(LYR):-15.6529
ROE:-122.61%
ROA:-51.62%
PB:1.43
PE(LYR):-0.07

Loading ...

Allarity Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
Mar 27

Allarity Therapeutics Closes $20 Million Non-Convertible Debt Financing With Streeterville Capital

Reuters
·
Mar 06

BRIEF-Allarity Therapeutics Closes $20 Million Financing To Accelerate The Advance Of Stenoparib Toward FDA Approval And Commercialization

Reuters
·
Mar 06

Allarity Therapeutics Closes $20 Million Financing to Accelerate the Advance of Stenoparib Toward FDA Approval and Commercialization

THOMSON REUTERS
·
Mar 06

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Relapsed SCLC Trial of Stenoparib Plus Temozolomide

Reuters
·
Feb 18

Allarity Therapeutics Doses First Patients in VA-Funded Phase 2 Trial Focused on Small Cell Lung Cancer with High Unmet Need

GlobeNewswire
·
Feb 18

Allarity Therapeutics Inc - Prospectus for Resale of 255,103 Shares of Common Stock by Selling Stockholder - SEC Filing

THOMSON REUTERS
·
Feb 13

Allarity announce enrollment open for Phase 2 trial of stenoparib, temozolomide

TIPRANKS
·
Feb 03

Allarity Therapeutics Announces That Its Collaborative Phase 2 Trial With the United States Veteran’s Administration Combining Stenoparib With Temozolomide in Relapsed Small Cell Lung Cancer Is NOW Open for Enrollment

THOMSON REUTERS
·
Feb 03

Allarity Therapeutics Partners with U.S. Department of Veterans Affairs for Phase 2 Cancer Trial

Reuters
·
Feb 03

Allarity Therapeutics Inc - on Jan 28, Co Entered Stock Purchase Agreement With Tumim Stone Capital - SEC Filing

THOMSON REUTERS
·
Jan 29

Allarity Therapeutics Inc - Company May Sell up to $6 Mln in Newly Issued Shares - SEC Filing

THOMSON REUTERS
·
Jan 29

Allarity Therapeutics Advances Stenoparib Toward FDA Approval After Strategic Realignment

Reuters
·
Dec 31, 2025

Allarity Therapeutics Raises $2.5 Million in Private Placement of Unregistered Shares

Reuters
·
Dec 23, 2025

Allarity Therapeutics Sets New CFO Compensation Package With $367,700 Salary and $160,000 RSUs

Reuters
·
Dec 08, 2025

BRIEF-Allarity Therapeutics Inc - To Offer Up To $50 Million In Securities

Reuters
·
Dec 03, 2025

Allarity Therapeutics Inc - to Offer up to $50 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Dec 03, 2025

Allarity Therapeutics's Q3 net loss narrows

Reuters
·
Nov 14, 2025

Allarity Therapeutics reports third quarter net loss of $2.8 million

Reuters
·
Nov 14, 2025

Allarity Therapeutics Q3 Operating Expenses USD 2.518 Million

THOMSON REUTERS
·
Nov 14, 2025